All Stories

  1. Disruption of ADAMTS13-Autoantibody Complexes with an ADAMTS13 Spacer Domain As a Potential Therapeutic Strategy for Immune Thrombotic Thrombocytopenic Purpura
  2. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy
  3. Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals
  4. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura
  5. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura
  6. Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma
  7. Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia
  8. Understanding thrombotic microangiopathies in children
  9. Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature
  10. Platelets Loaded with Recombinant ADAMTS13 Are Efficacious in Inhibiting Arterial Thrombosis Under Flow: A Potential Novel Therapeutic for Acquired TTP
  11. Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development
  12. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation
  13. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics
  14. Mutations in Coagulation Factor VIII Are Associated with More Favorable Outcome in Patients with Cutaneous Melanoma
  15. ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis
  16. Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity: comment
  17. Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation
  18. Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage
  19. ADAMTS13-/-zebrafish Model Created By Crispr/Cas Reveals a Novel Role of ADAMTS13 in Vascular Development and Prothrombotic Phenotype
  20. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A
  21. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura
  22. Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A
  23. Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura
  24. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP
  25. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro
  26. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model
  27. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia
  28. ADAMTS13 and von Willebrand factor interactions
  29. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome
  30. Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease
  31. Knockout of Adamts7 , a Novel Coronary Artery Disease Locus in Humans, Reduces Atherosclerosis in Mice
  32. Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models
  33. ADAMTS13, lucky to have a hydrophobic pocket
  34. ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura
  35. Current Status in Diagnosis and Treatment of Hereditary Thrombotic Thrombocytopenic Purpura
  36. ADAMTS13: Structure and Function
  37. ADAMTS13 and Angiogenesis
  38. Exploiting the kinetic interplay between GPIb -VWF binding interfaces to regulate hemostasis and thrombosis
  39. ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2
  40. Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura
  41. DNase, ADAMTS13, and iPAD4: good for the heart
  42. Carboxyl Terminus of ADAMTS13 Directly Inhibits Platelet Aggregation and Ultra Large von Willebrand Factor String Formation Under Flow in a Free-Thiol-Dependent Manner
  43. Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway
  44. Structure-function and regulation of ADAMTS-13 protease
  45. Compromised shear-dependent cleavage of type 2N von Willebrand factor variants by ADAMTS13 in the presence of factor VIII
  46. Ticlopidine‐associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR)
  47. AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura
  48. ADAMTS13, TTP and Beyond
  49. Biochemistry and Physiological Functions of ADAMTS7 Metalloprotease
  50. Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR)
  51. Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders
  52. Light Chain of Factor VIII Is Sufficient for Accelerating Cleavage of von Willebrand Factor by ADAMTS13 Metalloprotease
  53. Genetic Ablation of Adamts13 Gene Dramatically Accelerates the Formation of Early Atherosclerosis in a Murine Model
  54. ADAMTS13 meets MR, then what?
  55. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice
  56. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
  57. Essential Domains of A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13 Metalloprotease Required for Modulation of Arterial Thrombosis
  58. A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura
  59. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura
  60. Toward a definition of “fresh” whole blood: an in vitro characterization of coagulation properties in refrigerated whole blood for transfusion
  61. Analysis of Morphology of Platelet Aggregates Formed on Collagen Under Laminar Blood Flow
  62. Factor VIII and Platelets Synergistically Accelerate Cleavage of von Willebrand Factor by ADAMTS13 under Fluid Shear Stress
  63. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura
  64. ADAMTS13 testing: why bother?
  65. Amino acid residues Arg659, Arg660, and Tyr661 in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor
  66. A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection
  67. von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size
  68. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site
  69. A team player: the disintegrin domain of ADAMTS13
  70. Thromboelastography of Patients After Fontan Compared with Healthy Children
  71. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989–2008)
  72. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy
  73. Correction of ADAMTS13 Deficiency by In Utero Gene Transfer of Lentiviral Vector encoding ADAMTS13 Genes
  74. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
  75. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells
  76. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13
  77. Pathogenesis of Thrombotic Microangiopathies
  78. Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura
  79. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow
  80. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts
  81. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo
  82. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo
  83. An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura
  84. The Proximal Carboxyl-terminal Domains of ADAMTS13 Determine Substrate Specificity and Are All Required for Cleavage of von Willebrand Factor
  85. Molecular Biology of ADAMTS13 and Diagnostic Utility of ADAMTS13 Proteolytic Activity and Inhibitor Assays
  86. Binding of platelet glycoprotein Ibα to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13
  87. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura
  88. Cleavage of the ADAMTS13 Propeptide Is Not Required for Protease Activity
  89. Cleavage of von Willebrand Factor Requires the Spacer Domain of the Metalloprotease ADAMTS13
  90. ADAMTS13 and TTP
  91. Mucin-like Domain of Enteropeptidase Directs Apical Targeting in Madin-Darby Canine Kidney Cells
  92. Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura
  93. Crystal structure of enteropeptidase light chain complexed with an analog of the trypsinogen activation peptide 1 1Edited by R. Huber
  94. Differential Activity of Diethylstilbestrol versus Estradiol As Neonatal Endocrine Disruptors in the Female Hamster (Mesocricetus auratus) Reproductive Tract1
  95. Apical Sorting of Bovine Enteropeptidase Does Not Involve Detergent-resistant Association with Sphingolipid-Cholesterol Rafts
  96. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice
  97. Activation of Thrombin-activable Fibrinolysis Inhibitor Requires Epidermal Growth Factor-like Domain 3 of Thrombomodulin and Is Inhibited Competitively by Protein C
  98. Structure of murine enterokinase (enteropeptidase) and expression in small intestine during development
  99. Bovine Proenteropeptidase Is Activated by Trypsin, and the Specificity of Enteropeptidase Depends on the Heavy Chain
  100. Effect of protein C inhibitor (PCI) on in vitro fertilization
  101. Protein C inhibitor (PCI)
  102. Serine protease inhibitors (serpins) in human seminal plasma: Concentrations and inhibition of acrosin
  103. Inhibition of acrosin by protein C inhibitor and localization of protein C inhibitor to spermatozoa
  104. Effect of protein C inhibitor (PCI) on in vitro fertilization